// App-Quantinova.ai

645 : An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis

Researchers

Presenter

  • Eric Gracey

Principal Investigators

  • Melissa Lim

  • Zoya Qaiyum

  • Yuriy Baglaenko

  • Wenyan Miao

  • Craig Masse

  • William Westlin

  • Robert D Inman

Medical Centers

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

  • Jounce Therapeutics, Cambridge, MA

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • lonomycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved